Successful tacrolimus treatment following renal transplant in a HIV-infected patient with raltegravir previously treated with a protease inhibitor based regimen

Drug Metabolism and Drug Interactions

Volumn 26, Issue 3, 2011, Pages 139-141

  Cousins, Darren ^a   Topping, Kate ^a   Lee, Vincent ^a   Sweeney, John ^b   Lawton, Mark ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b ROYAL PRESTON HOSPITAL   (United Kingdom)

Author keywords

atazanavir; HIV; tacrolimus

Indexed keywords

ABACAVIR; ATAZANAVIR; CYTOCHROME P450 3A4; ETRAVIRINE; GLUCURONOSYLTRANSFERASE 1A1; MYCOPHENOLIC ACID; PREDNISOLONE; RALTEGRAVIR; RITONAVIR; TACROLIMUS; TENOFOVIR;

ACUTE KIDNEY TUBULE NECROSIS; ADULT; ARTICLE; CADAVER KIDNEY; CASE REPORT; CONSCIOUSNESS; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG REEXPOSURE; DRUG SUBSTITUTION; FEMALE; HEMODIALYSIS; HIV ASSOCIATED NEPHROPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; SIDE EFFECT; VIREMIA; VIRUS LOAD;

ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MIDDLE AGED; PYRROLIDINONES; TACROLIMUS;

EID: 80053970961     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.2011.026     Document Type: Article

References (9)

1. Lankisch TO, Moebius U, Wehmeier M, Behrens G, Manns MP, Schimdt RE, et al.Gilbert ' s disease and atazanavir: from phenotype to UDP- glucuronosyltransferase haplotype.Hepatology 2006;44:1324-32. (Pubitemid 44748383)
2. Bickel M, Anadol E, Vogel M, Hofmann WP, von Hentig N, Kuetscher J, et al.Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir.J Antimicrob Chemother 2010;65:999-1004.
3. Backman L, Nicar M, Levy M, Distant D, Eisenstein C, Renard T, et al.FK506 trough levels in whole blood and plasma in liver transplant recipients.Correlation with clinical events and side effects.Transplantation 1994;57:519-25.
4. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, et al., for the European-Australian Collaborative Ritonavir Study Group.A short term study of the safety, pharmacokinetics and effi cacy of ritonavir - an inhibitor of HIV-1 protease.N Engl J Med 1995;333:1528-33.
5. Schonder KS, Shullo MA, Okusanya O.Tacrolimus and lopinavir/ ritonavir interaction in lever transplantation.Ann Pharmacother 2003;37:1793-6. (Pubitemid 37466573)
6. Jain AB, Venkataramanan R, Eghtesad B, Marcos A, Ragni M, Shapiro R, et al.Effect of co-administered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients.Liver Transpl 2003;9:954-60. (Pubitemid 37098844)
7. King CD, Rios GR, Green MD, Tephly TR.UDP lucuronosyltransferases.Curr Drug Metab 2001;1:143-61.
8. Hicks C, Guilick RM.Raltegravir: the fi rst HIV type 1 integrase inhibitor.Clin Infect Dis 2009;48:931-9.
9. Eron JJ, Young B, Cooper DA, Youle M, Dejesus E, Andrade- Villanueva J, et al.Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIVinfected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.Lancet 2010;375:396-407.